Vectofusin-1 improves transduction of primary human cells with diverse retroviral and lentiviral pseudotypes, enabling robust, automated closed-system manufacturing

C Radek, O Bernadin, K Drechsel, N Cordes… - Human gene …, 2019 - liebertpub.com
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …
被引用次数：34 相关文章

Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel… - Human Gene …, 2019 - univ-evry.hal.science
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …

Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel, N Cordes… - Human Gene …, 2019 - hal.science
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …
[HTML] nih.gov

[HTML][HTML] Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel, N Cordes… - Human Gene …, 2019 - ncbi.nlm.nih.gov
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …

[引用][C] Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel, N Cordes… - Human Gene …, 2019 - cir.nii.ac.jp
Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and
Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing | CiNii …

Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel… - Human gene …, 2019 - pubmed.ncbi.nlm.nih.gov
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …
[PDF] semanticscholar.org

[PDF][PDF] Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel… - HUMAN GENE … - pdfs.semanticscholar.org
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …

Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel, N Cordes… - Human Gene …, 2019 - europepmc.org
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …

Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System …

C Radek, O Bernadin, K Drechsel… - Human gene …, 2019 - pubmed.ncbi.nlm.nih.gov
Cell and gene therapies are finally becoming viable patient treatment options, with both T
cell-and hematopoietic stem cell (HSC)-based therapies being approved to market in …